Alphatec Holdings, Inc. (NASDAQ:ATEC) Shares Sold by Mesirow Financial Investment Management Inc.

Mesirow Financial Investment Management Inc. cut its holdings in shares of Alphatec Holdings, Inc. (NASDAQ:ATEC) by 24.4% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 23,867 shares of the medical technology company’s stock after selling 7,706 shares during the period. Alphatec makes up about 1.6% of Mesirow Financial Investment Management Inc.’s investment portfolio, making the stock its 19th largest holding. Mesirow Financial Investment Management Inc.’s holdings in Alphatec were worth $329,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. First Light Asset Management LLC grew its stake in shares of Alphatec by 97.0% in the 4th quarter. First Light Asset Management LLC now owns 5,976,851 shares of the medical technology company’s stock worth $90,310,000 after purchasing an additional 2,943,310 shares during the last quarter. Cerity Partners LLC acquired a new position in Alphatec in the fourth quarter worth approximately $28,451,000. Artisan Partners Limited Partnership bought a new position in shares of Alphatec in the fourth quarter valued at $19,050,000. Goldman Sachs Group Inc. lifted its position in shares of Alphatec by 93.9% during the 4th quarter. Goldman Sachs Group Inc. now owns 1,451,499 shares of the medical technology company’s stock valued at $21,932,000 after acquiring an additional 702,950 shares during the last quarter. Finally, Intrinsic Edge Capital Management LLC boosted its stake in shares of Alphatec by 72.2% during the 4th quarter. Intrinsic Edge Capital Management LLC now owns 1,599,849 shares of the medical technology company’s stock worth $24,174,000 after acquiring an additional 670,788 shares in the last quarter. 66.35% of the stock is currently owned by institutional investors and hedge funds.

Alphatec Stock Performance

Shares of Alphatec stock traded up $0.08 on Wednesday, reaching $9.98. The stock had a trading volume of 458,708 shares, compared to its average volume of 1,628,218. Alphatec Holdings, Inc. has a fifty-two week low of $8.66 and a fifty-two week high of $19.14. The business’s 50-day moving average price is $10.94 and its two-hundred day moving average price is $13.29. The stock has a market cap of $1.40 billion, a P/E ratio of -6.68 and a beta of 1.40. The company has a debt-to-equity ratio of 13.63, a quick ratio of 1.49 and a current ratio of 2.39.

Alphatec (NASDAQ:ATEC) last announced its earnings results on Tuesday, May 7th. The medical technology company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.01). Alphatec had a negative return on equity of 1,767.81% and a negative net margin of 37.45%. The company had revenue of $138.48 million for the quarter, compared to the consensus estimate of $134.07 million. During the same period last year, the firm posted ($0.40) EPS. The company’s revenue was up 26.9% compared to the same quarter last year. On average, sell-side analysts forecast that Alphatec Holdings, Inc. will post -1.04 EPS for the current year.

Insider Buying and Selling at Alphatec

In other news, CFO John Todd Koning sold 37,500 shares of the company’s stock in a transaction dated Wednesday, April 24th. The shares were sold at an average price of $12.82, for a total value of $480,750.00. Following the sale, the chief financial officer now owns 393,356 shares of the company’s stock, valued at approximately $5,042,823.92. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In related news, CFO John Todd Koning sold 37,500 shares of the company’s stock in a transaction dated Wednesday, April 24th. The shares were sold at an average price of $12.82, for a total transaction of $480,750.00. Following the transaction, the chief financial officer now owns 393,356 shares in the company, valued at approximately $5,042,823.92. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, General Counsel Tyson Eliot Marshall sold 50,232 shares of the company’s stock in a transaction dated Wednesday, June 12th. The shares were sold at an average price of $10.88, for a total transaction of $546,524.16. Following the transaction, the general counsel now owns 245,638 shares in the company, valued at $2,672,541.44. The disclosure for this sale can be found here. Insiders own 22.80% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on ATEC. Needham & Company LLC reaffirmed a “buy” rating and set a $23.00 target price on shares of Alphatec in a research report on Wednesday, May 8th. Canaccord Genuity Group reiterated a “buy” rating and issued a $25.00 target price on shares of Alphatec in a report on Wednesday, March 20th. Finally, Piper Sandler dropped their target price on shares of Alphatec from $19.00 to $17.00 and set an “overweight” rating on the stock in a research report on Wednesday, May 8th. One analyst has rated the stock with a sell rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $21.75.

Alphatec Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.